108 related articles for article (PubMed ID: 22393091)
41. KRAS mutations in traditional serrated adenomas from Korea herald an aggressive phenotype.
Kim KM; Lee EJ; Kim YH; Chang DK; Odze RD
Am J Surg Pathol; 2010 May; 34(5):667-75. PubMed ID: 20305537
[TBL] [Abstract][Full Text] [Related]
42. KRAS mutation is associated with lung metastasis in patients with curatively resected colorectal cancer.
Tie J; Lipton L; Desai J; Gibbs P; Jorissen RN; Christie M; Drummond KJ; Thomson BN; Usatoff V; Evans PM; Pick AW; Knight S; Carne PW; Berry R; Polglase A; McMurrick P; Zhao Q; Busam D; Strausberg RL; Domingo E; Tomlinson IP; Midgley R; Kerr D; Sieber OM
Clin Cancer Res; 2011 Mar; 17(5):1122-30. PubMed ID: 21239505
[TBL] [Abstract][Full Text] [Related]
43. BRAF/KRAS gene sequencing of sebaceous neoplasms after mismatch repair protein analysis.
Cornejo KM; Hutchinson L; Deng A; Tomaszewicz K; Welch M; Lyle S; Dresser K; Cosar EF
Hum Pathol; 2014 Jun; 45(6):1213-20. PubMed ID: 24767862
[TBL] [Abstract][Full Text] [Related]
44. KRAS and BRAF mutational status in primary colorectal tumors and related metastatic sites: biological and clinical implications.
Italiano A; Hostein I; Soubeyran I; Fabas T; Benchimol D; Evrard S; Gugenheim J; Becouarn Y; Brunet R; Fonck M; François E; Saint-Paul MC; Pedeutour F
Ann Surg Oncol; 2010 May; 17(5):1429-34. PubMed ID: 20049644
[TBL] [Abstract][Full Text] [Related]
45. mTORC1 upregulation via ERK-dependent gene expression change confers intrinsic resistance to MEK inhibitors in oncogenic KRas-mutant cancer cells.
Komatsu N; Fujita Y; Matsuda M; Aoki K
Oncogene; 2015 Nov; 34(45):5607-16. PubMed ID: 25703330
[TBL] [Abstract][Full Text] [Related]
46. [BRAF gene mutation in wild-type KRAS patients with colorectal cancers].
Roa I; Game A; Bizama C; Schalper K
Rev Med Chil; 2014 Jan; 142(1):55-60. PubMed ID: 24861115
[TBL] [Abstract][Full Text] [Related]
47. Functional TP53 mutations have no impact on response to cytotoxic agents in metastatic colon cancer.
Netter J; Lehmann-Che J; Lambert J; Tallet A; Lourenco N; Soliman H; Bertheau P; Pariente B; Chirica M; Pocard M; Allez M; De The H; Gornet JM
Bull Cancer; 2015 Feb; 102(2):117-25. PubMed ID: 25609485
[TBL] [Abstract][Full Text] [Related]
48. Possible role of Cdx2 in the serrated pathway of colorectal cancer characterized by BRAF mutation, high-level CpG Island methylator phenotype and mismatch repair-deficiency.
Dawson H; Galván JA; Helbling M; Muller DE; Karamitopoulou E; Koelzer VH; Economou M; Hammer C; Lugli A; Zlobec I
Int J Cancer; 2014 May; 134(10):2342-51. PubMed ID: 24166180
[TBL] [Abstract][Full Text] [Related]
49. Hyperplastic polyps identified during screening endoscopy: reevaluated by histological examinations and genetic alterations.
Lin YC; Chiu HM; Lee YC; Shun CT; Wang HP; Wu MS
J Formos Med Assoc; 2014 Jul; 113(7):417-21. PubMed ID: 24961182
[TBL] [Abstract][Full Text] [Related]
50. Efficacy of triplet combination chemotherapy with oxaliplatin, irinotecan and capecitabine (OCX) in metastatic colorectal cancer in relation to RAS/RAF mutation status: results of a retrospective analysis.
Brunner S; von Moos R; Mey U; Camenisch Gross U; Freyholdt T; Cathomas R
Oncol Res Treat; 2014; 37(11):646-52. PubMed ID: 25427581
[TBL] [Abstract][Full Text] [Related]
51. Combining molecular markers with the TNM staging system to improve prognostication in stage II and III colon cancer: are we ready yet?
Sinicrope FA; Shi Q
J Natl Cancer Inst; 2012 Nov; 104(21):1616-8. PubMed ID: 23104213
[No Abstract] [Full Text] [Related]
52. An uphill battle downstream of RAF.
Collisson EA
J Clin Oncol; 2011 Jun; 29(17):2298-300. PubMed ID: 21519020
[No Abstract] [Full Text] [Related]
53. Ovarian cancer : making its own rules-again.
Kohn EC; Hurteau J
Cancer; 2013 Feb; 119(3):474-6. PubMed ID: 23233093
[TBL] [Abstract][Full Text] [Related]
54. Molecular alterations of appendiceal serrated lesions.
Choi EK; Kim D; Divatia M; Takei H
Hum Pathol; 2015 Jul; 46(7):1062-3. PubMed ID: 25934250
[No Abstract] [Full Text] [Related]
55. Vitamin C as Cancer Destroyer, Investigating Sulfhydration, and the Variability in CFTR Interactome.
Chem Biol; 2015 Dec; 22(12):1575-6. PubMed ID: 26687480
[TBL] [Abstract][Full Text] [Related]
56. Gene-expression forum: Decoy for microRNAs.
Rigoutsos I; Furnari F
Nature; 2010 Jun; 465(7301):1016-7. PubMed ID: 20577197
[No Abstract] [Full Text] [Related]
57. Wild-type RAS: keeping mutant RAS in CHK.
Anastassiadis T; Brown EJ
Cancer Cell; 2014 Feb; 25(2):137-8. PubMed ID: 24525230
[TBL] [Abstract][Full Text] [Related]
58. Genetic events in the development of colon cancer.
Rumsby P; Davie S
Food Chem Toxicol; 1995 Apr; 33(4):328-30. PubMed ID: 7737606
[No Abstract] [Full Text] [Related]
59. Next-generation sequencing in the genomic profiling of synchronous colonic carcinomas: comment on Li et al (2015).
Malapelle U; De Stefano A; Carlomagno C; Bellevicine C; Troncone G
J Clin Pathol; 2015 Nov; 68(11):946-7. PubMed ID: 26139632
[No Abstract] [Full Text] [Related]
60. Enriching mutant sequences by modulating the denaturation time during PCR.
Murphy DM; Castellanos-Rizaldos E; Makrigiorgos GM
Clin Chem; 2014 Jul; 60(7):1014-6. PubMed ID: 24799525
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
